BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22847983)

  • 1. Systemic mastocytosis associated with t(8;21) acute myeloid leukemia in a child: detection of the D816A mutation of KIT.
    Yabe M; Masukawa A; Kato S; Yabe H; Nakamura N; Matsushita H
    Pediatr Blood Cancer; 2012 Dec; 59(7):1313-6. PubMed ID: 22847983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22).
    Johnson RC; Savage NM; Chiang T; Gotlib JR; Cherry AM; Arber DA; George TI
    Am J Clin Pathol; 2013 Oct; 140(4):525-35. PubMed ID: 24045550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
    Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
    Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia.
    Mahadeo KM; Wolgast L; McMahon C; Cole PD
    Pediatr Blood Cancer; 2011 Oct; 57(4):684-7. PubMed ID: 21671435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients.
    Won D; Chi HS; Shim H; Jang S; Park CJ; Lee JH
    Leuk Res; 2013 Aug; 37(8):883-8. PubMed ID: 23683787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
    Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
    Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.
    Wakita S; Yamaguchi H; Miyake K; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2011 Sep; 25(9):1423-32. PubMed ID: 21606963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic mastocytosis with associated acute myeloid leukemia with t (8; 21) (q22; q22).
    Gadage VS; Kadam Amare PS; Galani KS; Mittal N
    Indian J Pathol Microbiol; 2012; 55(3):409-12. PubMed ID: 23032848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acute myeloid leukemia evolving from KIT D816-mutated systemic mastocytosis relapsing two months after completion of chemotherapy].
    Harao T; Yamada A; Kinoshita M; Sawa D; Saito Y; Kamimura S; Miyachi H; Ogino T; Kodama Y; Okamoto Y; Kawano Y; Moritake H
    Rinsho Ketsueki; 2019; 60(5):378-381. PubMed ID: 31167998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
    Wang YY; Zhou GB; Yin T; Chen B; Shi JY; Liang WX; Jin XL; You JH; Yang G; Shen ZX; Chen J; Xiong SM; Chen GQ; Xu F; Liu YW; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1104-9. PubMed ID: 15650049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
    Pullarkat V; Bedell V; Kim Y; Bhatia R; Nakamura R; Forman S; Sun J; Senitzer D; Slovak ML
    Leuk Res; 2007 Feb; 31(2):261-5. PubMed ID: 16876862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
    Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
    Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t(8;21) in Japan: a study of the Japanese childhood AML cooperative study group.
    Shimada A; Taki T; Kubota C; Itou T; Tawa A; Horibe K; Tsuchida M; Hanada R; Tsukimoto I; Hayashi Y;
    Leukemia; 2007 Oct; 21(10):2218-9. PubMed ID: 17525721
    [No Abstract]   [Full Text] [Related]  

  • 15. FLT3-internal tandem duplication in a pediatric patient with t(8;21) acute myeloid leukemia.
    Kawamura M; Kaku H; Ito T; Funata N; Taki T; Shimada A; Hayashi Y
    Cancer Genet Cytogenet; 2010 Dec; 203(2):292-6. PubMed ID: 21156247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
    Jawhar M; Döhner K; Kreil S; Schwaab J; Shoumariyeh K; Meggendorfer M; Span LLF; Fuhrmann S; Naumann N; Horny HP; Sotlar K; Kubuschok B; von Bubnoff N; Spiekermann K; Heuser M; Metzgeroth G; Fabarius A; Klein S; Hofmann WK; Kluin-Nelemans HC; Haferlach T; Döhner H; Cross NCP; Sperr WR; Valent P; Reiter A
    Leukemia; 2019 May; 33(5):1124-1134. PubMed ID: 30635631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].
    Li WY; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):797-801. PubMed ID: 19176031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
    Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
    Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia'.
    Rabade N; Tembhare P; Patkar N; Amare P; Arora B; Subramanian PG; Gujral S
    Indian J Pathol Microbiol; 2016; 59(3):407-9. PubMed ID: 27510692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
    Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
    Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.